Hi,
moomoo ID:NaN
Log Out
ENGLISH
  • ENGLISH
  • 中文繁体
  • 中文简体
donwloadimg

Download App

Log in to access Online Inquiry
Multi-dimentional Analyses
Company Valuation Capital Tracking Short Selling Data
Moomoo > Quotes > NUVL Nuvalent > Detailed Quotes

NUVL Nuvalent

19.700
+2.260+12.96%
Close 09/28 16:00 ET
19.7000.0000.00%
Post Mkt Price 09/28 16:02 ET
High
20.000
Open
17.670
Turnover
3.16M
Low
17.650
Pre Close
17.440
Volume
162.31K
Market Cap
953.74M
P/E(TTM)
Loss
52wk High
31.430
Shares
48.41M
P/E(Static)
Loss
52wk Low
7.090
Float Cap
349.37M
Bid/Ask %
0.00%
Historical High
40.821
Shs Float
17.73M
Volume Ratio
1.52
Historical Low
7.090
Dividend TTM
--
Div Yield TTM
--
P/B
3.77
Dividend LFY
--
Div Yield LFY
--
Turnover Ratio
0.92%
Amplitude
13.48%
Avg Price
19.454
Lot Size
1
Float Cap
349.37M
Bid/Ask %
0.00%
Historical High
40.821
Shs Float
17.73M
Volume Ratio
1.52
Historical Low
7.090
Dividend TTM
--
P/B
3.77
Dividend LFY
--
Turnover Ratio
0.92%
Amplitude
13.48%
Avg Price
19.454
Lot Size
1
Price Forecast

No Data

News

Comment

Company Overview More
Nuvalent, Inc. operates as a preclinical stage biopharmaceutical company. The company creates precisely targeted therapies for patients with cancer designed to overcome the limitations of existing therapies for clinically proven kinase targets. Its focus its discovery efforts on small molecule inhibitors of kinases, a class of cellular targets that can play a central role in cancer growth and proliferation. The company was founded in January 2017 and is headquartered Cambridge, MA.
CEO: Dr. James R. Porter, PhD
Market: NASDAQ
Hot List
TradeSearchNews
SymbolLatest price%Chg

Loading...